These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28268208)

  • 1. The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma.
    Cong L; Hu L
    Int Immunopharmacol; 2017 May; 46():75-79. PubMed ID: 28268208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.
    Shi Y; Shen G; Zeng Y; Ju M; Chen X; He C; Liang L; Ge X; Sun X; Di X
    Int Immunopharmacol; 2023 Oct; 123():110773. PubMed ID: 37562292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative maximal voluntary ventilation, hemoglobin, albumin, lymphocytes and platelets predict postoperative survival in esophageal squamous cell carcinoma.
    Hu SJ; Zhao XK; Song X; Lei LL; Han WL; Xu RH; Wang R; Zhou FY; Wang L; Wang LD
    World J Gastroenterol; 2021 Jan; 27(4):321-335. PubMed ID: 33584065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The preoperative hemoglobin, albumin, lymphocyte and platelet (HALP) score is a useful predictor in patients with resectable esophageal squamous cell carcinoma.
    Feng JF; Wang L; Yang X
    Bosn J Basic Med Sci; 2021 Dec; 21(6):773-781. PubMed ID: 33974528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet to lymphocyte ratio is a predictive marker of prognosis and therapeutic effect of postoperative chemotherapy in non-metastatic esophageal squamous cell carcinoma.
    Yang Y; Xu H; Zhou L; Deng T; Ning T; Liu R; Zhang L; Wang X; Ge S; Li H; Ba Y
    Clin Chim Acta; 2018 Apr; 479():160-165. PubMed ID: 29325800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
    Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
    Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.
    Liang S; Li C; Gao Z; Li J; Zhao H; Yu J; Meng X
    Int Immunopharmacol; 2021 Jan; 90():107178. PubMed ID: 33218939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response evaluation with endoscopic ultrasound and computed tomography in esophageal squamous cell carcinoma treated by definitive chemoradiotherapy.
    Chang WL; Wang WL; Chung TJ; Lin FC; Yen CJ; Lai WW; Yang HB; Sheu BS
    J Gastroenterol Hepatol; 2015 Mar; 30(3):463-9. PubMed ID: 25088453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Yamakita I; Kurokawa T; Okada M
    Ann Thorac Surg; 2016 Oct; 102(4):1132-9. PubMed ID: 27319990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
    Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ
    Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
    Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer.
    Xie X; Luo KJ; Hu Y; Wang JY; Chen J
    Dis Esophagus; 2016 Jan; 29(1):79-85. PubMed ID: 25410116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy.
    Peng D; Zhang CJ; Tang Q; Zhang L; Yang KW; Yu XT; Gong Y; Li XS; He ZS; Zhou LQ
    BMC Urol; 2018 Mar; 18(1):20. PubMed ID: 29544476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy.
    Okamoto H; Fujishima F; Kamei T; Nakamura Y; Ozawa Y; Miyata G; Nakano T; Katsura K; Abe S; Taniyama Y; Sakurai T; Teshima J; Hikage M; Sasano H; Ohuchi N
    BMC Cancer; 2015 Mar; 15():208. PubMed ID: 25880782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of platinum analogue-based chemotherapy for advanced esophageal squamous cell carcinoma and prognostic factors].
    Yang L; Wang JW; Shi YK
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1233-7. PubMed ID: 21756792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.